Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

ADAPY holding history

Adaptimmune Therapeutics PLC in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ADAPY overviewAll 13F holders of ADAPYFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of ADAPY by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−3,666,061−100.0%Sold outHolders
Q3 20253,666,061$476.6K<0.1%−566,207−13.4%ReducedHolders
Q2 20254,232,268$1.01M<0.1%+1,516,321+55.8%AddedHolders
Q1 20252,715,947$535.0K<0.1%+1,391,083+105.0%AddedHolders
Q4 20241,324,864$713.7K<0.1%−374,161−22.0%ReducedHolders
Q3 20241,699,025$1.61M<0.1%+1,258,193+285.4%AddedHolders
Q2 2024440,832$429.8K<0.1%+67,551+18.1%AddedHolders
Q1 2024373,281$589.8K<0.1%−1,583,377−80.9%ReducedHolders
Q4 20231,956,658$1.55M<0.1%−94,688−4.6%ReducedHolders
Q3 20232,051,346$1.60M<0.1%−25,826−1.2%ReducedHolders
Q2 20232,077,172$1.92M<0.1%−175,252−7.8%ReducedHolders
Q1 20232,252,424$2.46M<0.1%−37,424−1.6%ReducedHolders
Q4 20222,289,848$3.34M<0.1%+22,082+1.0%AddedHolders
Q3 20222,267,766$2.44M<0.1%+187,297+9.0%AddedHolders
Q2 20222,080,469$3.54M<0.1%+27,034+1.3%AddedHolders
Q1 20222,053,435$4.23M<0.1%−190,038−8.5%ReducedHolders
Q4 20212,243,473$8.41M<0.1%+1,908,502+569.8%AddedHolders
Q3 2021334,971$1.73M<0.1%−1,953,560−85.4%ReducedHolders
Q2 20212,288,531$9.75M<0.1%−2,435,031−51.6%ReducedHolders
Q1 20214,723,562$25.1M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.